COL18A1 and hereditary angioedema: With the same limitations as for pdC1-INH, there is evidence that blocking bradykinin-2 receptors with icatibant is an effective intervention for treating attacks in various body sites in the majority of HAE nC1-INH patients [15, 39, 100].